Impax Receives FDA Non-Approvable Letter for Vadova
Posted on: Monday, 4 February 2008, 12:00 CST
Impax Laboratories has received a non-approvable letter from the FDA concerning its new drug application and subsequent submissions for Vadova tablets.
The FDA's action was primarily based on unresolved issues relating to product nomenclature and its belief of a likelihood of medication errors resulting from confusion of Vadova with other marketed forms of carbidopa/levodopa.
Larry Hsu, president and CEO of Impax Laboratories, said: "We believe that Vadova represents a significant improvement in the choices available to patients in the treatment of the symptoms of Parkinson's disease and will continue to pursue discussions with the FDA concerning this decision and we are evaluating all options for the product."
Source: Datamonitor
Related Articles
- IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options
- IMPAX Files Amendment to Vadova(TM) NDA
- FDA Says Impax Parkinson's Drug Not Approvable
- Impax's Vadova is 'Non-Approvable'
- IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
- FDA Law Enforcement: Critical to Product Safety
- FDA Cites Possible Suicide Link in Paxil
- FDA OKs Anti-Nausea Pill for Chemotherapy
- FDA Backs Anti-Nausea Drug for Some
 |
 |
User Comments (0)
RSS Feeds